MarketPulse

breast cancer immunotherapy

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences' GLSI-100 Data Gets ASCO Platform; 70-80% Recurrence Reduction Shown

Greenwich LifeSciences' GLSI-100 breast cancer immunotherapy receives ASCO 2026 abstract acceptance, showing 70-80% recurrence reduction in Phase III trial.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Doubles Market for GP2 Cancer Therapy With Expanded Patent Claims

Greenwich LifeSciences expands GLSI-100 breast cancer therapy addressable market by 100% through new patent claims extending to 2045, adding 88,000 potential patients annually.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Scales GP2 Production as Phase III Trial Hits Manufacturing Milestone

Greenwich LifeSciences deploys commercially manufactured GP2 across all 40 FLAMINGO-01 trial sites following FDA approval, scaling production capacity significantly.
GLSIFDA approvalcommercial manufacturing